Literature DB >> 6873152

The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

W H Steele, D J King, H E Barber, G M Hawksworth, A A Dawson, J C Petrie.   

Abstract

The protein binding of vinblastine was measured in the serum from 6 normal subjects and 9 patients with Hodgkin's disease. Cellulose acetate electrophoresis showed that the predominant binding protein fractions were the alpha 1- and alpha 2-globulins with little binding to albumin and beta- and gamma-globulins. At a serum concentration of 10 nM a significantly lower percentage bound was found in the patient group (p = 0.001). Binding to both groups was very high at 99.7% bound in the normal subjects and 98.9% bound in the patient group. Binding in both groups was best described by a two class protein binding model with higher and lower affinity binding sites. No significant difference was found on inter-group comparisons of binding parameter values.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873152     DOI: 10.1007/bf00542223

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances.

Authors:  J G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

2.  The effect of neoplastic and allied diseases on the concentrations of the plasma proteins.

Authors:  G B MIDER; E L ALLING; J J MORTON
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

3.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 4.  A decade of combination chemotherapy of advanced Hodgkin's disease.

Authors:  V T DeVita; G P Canellos; J H Moxley
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

5.  The binding of vinblastine by platelets in the rat.

Authors:  H F Hebden; J R Hadfield; C T Beer
Journal:  Cancer Res       Date:  1970-05       Impact factor: 12.701

6.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  The reversible binding of vinblastine to platelets: implications for therapy.

Authors:  J G Kelton; J W McDonald; R M Barr; I Walker; W Nicholson; P B Neame; C Hamid; T Y Wong; J Hirsh
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

8.  Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma.

Authors:  L F Chio; C J Oon
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

9.  Serum acute-phase proteins and immunoglobulins in patients with gliomas.

Authors:  J F Weiss; R A Morantz; W P Bradley; P B Chretien
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

10.  Radioimmunoassay of vinblastine and vincristine.

Authors:  J D Teale; J M Clough; V Marks
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

View more
  4 in total

1.  Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique.

Authors:  S Urien; G Bastian; C Lucas; J P Bizzari; J P Tillement
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

2.  Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides.

Authors:  K A Peck-Miller; R P Darveau; H P Fell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood.

Authors:  S Urien; F Brée; F Breillout; G Bastian; A Krikorian; J P Tillement
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.